Martin Haluzík on Residual Cardiovascular Risk in Coronary Artery Disease
Martin Haluzík, Professor of Medicine at Institute for Clinical and Experimental Medicine, shared on LinkedIn:
”Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
Excellent review on residual cardiovascular risk in coronary artery disease just published in Nature Reviews Cardiology by Mattia Galli and colleagues.
Despite substantial advances in the secondary prevention of cardiovascular disease, atherosclerosis of the coronary arteries and its consequences remain the leading cause of death worldwide.
Residual cardiovascular risk refers to the ongoing risk of recurrent cardiovascular events that persists in patients with coronary artery disease despite receiving optimal secondary prevention treatment and effective control of conventional risk factors.
Lifestyle modification and therapies modulating thrombosis, blood pressure and LDL-cholesterol levels represent the standard approach for the prevention of recurrent cardiovascular events in patients with coronary artery disease.
However, current evidence-based therapies and lifestyle modification strategies only partially modulate the pathophysiological pathways involved in the progression and destabilization of atherosclerotic disease, and other mechanisms might have an important role, accounting, at least in part, for the residual cardiovascular risk in these patients.
In this Review, the authors appraise the available evidence and latest insights into the mechanisms and associated biomarkers of recurrent adverse cardiovascular events and provide perspectives on strategies to reduce residual cardiovascular risk in patients with coronary artery disease.
- Very well-written and comprehensive paper
- Great overview of traditional, emerging and novel CV risk markers
- Perfect description of subtypes of residual risks such as thrombotic, lipid, metabolic and inflammatory and the strategies for their mitigation
- Final subchapter on emerging factors such as exposome, microbiota and much more
A must read paper! Congratulations to the authors!”
Read the full article here.
Article: Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
Authors: Mattia Galli, Antonio Abbate, Marc P. Bonaca, Filippo Crea, Maurizio Forte, Giacomo Frati, Mario Gaudino, C. Michael Gibson, Diana A. Gorog, Roxana Mehran, Rocco A. Montone, Michelle L. O’Donoghue, P. Gabriel Steg, Sebastiano Sciarretta, Dominick J. Angiolillo
Stay updated on all scientific advances with Hemostasis Today.
-
May 1, 2026, 08:04Erwin Loh: Your Morning Coffee May Help Protect Your Body Against Aging
-
May 1, 2026, 07:50Wolfgang Miesbach: Practice-Changing Insights on the Efficacy and Safety of Platelet Transfusions at the EHA-SWG
-
May 1, 2026, 07:27What Does “Successful Ageing” Really Mean for People Living with Haemophilia Today? – EAHAD
-
Apr 30, 2026, 18:19Deva Nanda TK: A Practical Overview of Dural Sinuses and The Venous Drainage of the Brain
-
Apr 30, 2026, 18:08Amrit Kaur Kaler: The Hidden Genetic Drivers of Thrombosis
-
Apr 30, 2026, 18:06Alejandro González Veliz: The Most Dangerous Mistake After Getting a Stent
-
Apr 30, 2026, 18:03Carmen Ruiz: First Arterial Mechanical Thrombectomy in New Zealand Using the ARTIX System
-
Apr 30, 2026, 17:52Simon Senanu: von Willebrand Disease May Be Missed Despite Normal Tests
-
Apr 30, 2026, 17:20José Antonio García Erce: Why Healthy Older Adults Should Keep Donating Blood?